How much will ViewRay owe in February?

The upcoming quarterly report is expected on the 11th of March 2021. The stock experiences an active upward rally. ViewRay Issuance Purchase of Equity Shares is fairly stable at the moment as compared to the past year. ViewRay reported Issuance Purchase of Equity Shares of 24.07 Million in 2020. Share Based Compensation is likely to rise to about 1 M in 2021, whereas Net Income Per Employee is likely to drop (377.7 K) in 2021. As many of us are excited about healthcare space, it is fair to break down ViewRay as a unique alternative.
Published over a year ago
View all stories for ViewRay | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

The company currently holds 66.76 M in liabilities with Debt to Equity (D/E) ratio of 0.44, which is about average as compared to similar companies. ViewRay has a current ratio of 3.07, suggesting that it is liquid enough and is able to pay its financial obligations when due.
ViewRay financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of ViewRay, including all of ViewRay's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of ViewRay assets, the company is considered highly leveraged. Understanding the composition and structure of overall ViewRay debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Watch out for price decline

Please consider monitoring ViewRay on a daily basis if you are holding a position in it. ViewRay is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as ViewRay stock to be traded above the $1 level to remain listed. If ViewRay stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is ViewRay's Liquidity

ViewRay financial leverage refers to using borrowed capital as a funding source to finance ViewRay ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ViewRay financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to ViewRay's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ViewRay's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between ViewRay's total debt and its cash.

Breaking down ViewRay Indicators

The entity reported the previous year's revenue of 55.03 M. Net Loss for the year was (117.02 M) with profit before overhead, payroll, taxes, and interest of 2.42 M.

Liabilities Breakdown

10 M
Deposit Liabilities
42.1 M
Current Liabilities
23.3 M
Long-Term Liabilities
Deposit Liabilities10.02 Million
Total Liabilities96.29 Million
Current Liabilities42.09 Million
Long-Term Liabilities23.26 Million

Can ViewRay build up on the current rise?

Jensen alpha is down to 0.27. It may suggest a possible volatility slide. ViewRay shows above-average downside volatility for the selected time horizon. We advise investors to inspect ViewRay further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ViewRay future alpha.

The Bottom Line

While some companies within the medical devices industry are still a little expensive, even after the recent corrections, ViewRay may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take up nor drop any shares of ViewRay at this time. The ViewRay risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ViewRay.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of ViewRay. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to [email protected]